STAT3 and neoplasm: For the first time, we demonstrate that while the tumor volumes are kept small as a result of paclitaxel treatment, populations of tumor cells within the residual tumors retain the activated JAK2/STAT3 pathway and are enriched in markers such as Oct4 and CD117.